Business
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an extension of its previously announced brokered private placement LIFE financing (the "Offering") consisting of a minimum of 5,714,285 units of the Company (each, a "Unit") at a post-consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000.
About this update from Biovaxys Technology Corp
[{"type":"text","content":"// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //","length":103,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an extension of its previously announced brokered private placement LIFE financing (the "Offering") consisting of a minimum of 5,714,285 units of the Company (each, a "Unit") at a post-consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000.","length":559,"tagName":"p"},{"type":"image","alt":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","displaySize":"","headline":null,"caption":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":63,"url":"https://media.zenfs.com/en/cnwgroup.com/cca0b1a397afc4499b82a11ef5413aff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9ulMxObQLWtbOLV3qJfMtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/cca0b1a397afc4499b82a11ef5413aff","width":400,"height":63}},"href":"https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Each Unit will consist of one (1) post-consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-consolidation price of $0.50 for a period of 36 months from the closing date of the Offering.","length":476,"tagName":"p"},{"type":"text","content":"The Company engaged Enclave Capital LLC ("Enclave"), D12 Capital Markets Inc. ("D12"), and D12's affiliate, Foundation Markets Inc., to act as agents (together the "Agents"). Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors ...